Immune biomarkers of anti-EGFR monoclonal antibody therapy

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 40-47

  Trivedi, S ^a   Concha Benavente, F ^a   Srivastava, R M ^a   Jie, H B ^a   Gibson, S P ^a   Schmitt, N C ^a   Ferris, R L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

EGFR; head and neck cancer; immune biomarkers; monoclonal antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CETUXIMAB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PANITUMUMAB; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; IMMUNOLOGY; MACROPHAGE; MULTIMODALITY CANCER THERAPY; PAPILLOMAVIRUS INFECTION; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BIOMARKERS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MACROPHAGES; PAPILLOMAVIRUS INFECTIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84979269480     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu156     Document Type: Review

References (104)

1. Bublil, E.M., Yarden, Y., The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19 (2007), 124–134.
2. Yarden, Y., Sliwkowski, M.X., Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001), 127–137.
3. Langer, C.J., Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 112 (2008), 2635–2645.
4. Blick, S.K., Scott, L.J., Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 67 (2007), 2585–2607.
5. Frampton, J.E., Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs 70 (2010), 1987–2010.
6. Bourhis, J., Lefebvre, J.L., Vermorken, J.B., Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?. Eur J Cancer 46 (2010), 1979–1989.
7. Cripps, C., Winquist, E., Devries, M.C., et al. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 17 (2010), 37–48.
8. Holubec, L., Liska, V., Matejka, V.M., et al. The role of cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res 32 (2012), 4007–4011.
9. Spiro, H., Cetuximab for metastatic colorectal cancer. N Engl J Med, 361, 2009, 95 author reply 96–97.
10. Amado, R.G., Wolf, M., Peeters, M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 1626–1634.
11. Noguchi, T., Ritter, G., Nishikawa, H., Antibody-based therapy in colorectal cancer. Immunotherapy 5 (2013), 533–545.
12. Adams, G.P., Weiner, L.M., Monoclonal antibody therapy of cancer. Nat Biotechnol 23 (2005), 1147–1157.
13. Bonner, J.A., Harari, P.M., Giralt, J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006), 567–578.
14. Cunningham, D., Humblet, Y., Siena, S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004), 337–345.
15. Dechant, M., Weisner, W., Berger, S., et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 68 (2008), 4998–5003.
16. Bibeau, F., Lopez-Crapez, E., Di Fiore, F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27 (2009), 1122–1129.
17. Foon, K.A., Yang, X.D., Weiner, L.M., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58 (2004), 984–990.
18. Lynch, D.H., Yang, X.D., Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 29 (2002), 47–50.
19. Schneider-Merck, T., Lammerts van Bueren, J.J., Berger, S., et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184 (2010), 512–520.
20. Lopez-Albaitero, A., Ferris, R.L., Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 133 (2007), 1277–1281.
21. Lopez-Albaitero, A., Lee, S.C., Morgan, S., et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58 (2009), 1853–1864.
22. Zhang, W., Gordon, M., Schultheis, A.M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25 (2007), 3712–3718.
23. Gill, G.N., Kawamoto, T., Cochet, C., et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259 (1984), 7755–7760.
24. Goldstein, N.I., Prewett, M., Zuklys, K., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (1995), 1311–1318.
25. Kim, E.S., Khuri, F.R., Herbst, R.S., Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13 (2001), 506–513.
26. Sharafinski, M.E., Ferris, R.L., Ferrone, S., et al. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32 (2010), 1412–1421.
27. Kruger, J.S., Reddy, K.B., Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 1 (2003), 801–809.
28. Vivanco, I., Sawyers, C.L., The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002), 489–501.
29. Ellerbroek, S.M., Halbleib, J.M., Benavidez, M., et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61 (2001), 1855–1861.
30. Bleeker, W.K., Lammerts van Bueren, J.J., van Ojik, H.H., et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173 (2004), 4699–4707.
31. Srivastava, R.M., Lee, S.C., Andrade Filho, P.A., et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 19 (2013), 1858–1872.
32. Yang, X.D., Jia, X.C., Corvalan, J.R., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 (2001), 17–23.
33. Vermorken, J.B., Stohlmacher-Williams, J., Davidenko, I., et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14 (2013), 697–710.
34. Ferris, R.L., Jaffee, E.M., Ferrone, S., Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28 (2010), 4390–4399.
35. Luedke, E., Jaime-Ramirez, A.C., Bhave, N., et al. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 152 (2012), 431–440.
36. Roda, J.M., Joshi, T., Butchar, J.P., et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 13 (2007), 6419–6428.
37. Pander, J., Gelderblom, H., Antonini, N.F., et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 46 (2010), 1829–1834.
38. Taylor, R.J., Chan, S.L., Wood, A., et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 58 (2009), 997–1006.
39. Musolino, A., Naldi, N., Bortesi, B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 (2008), 1789–1796.
40. Tamura, K., Shimizu, C., Hojo, T., et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 22 (2011), 1302–1307.
41. Li, T., Perez-Soler, R., Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4 (2009), 107–119.
42. Abdullah, S.E., Haigentz, M. Jr, Piperdi, B., Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management. Chemother Res Pract, 2012, 2012, 351210.
43. Perez-Soler, R., Saltz, L., Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 (2005), 5235–5246.
44. Pollack, B.P., Sapkota, B., Cartee, T.V., Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 17 (2011), 4400–4413.
45. Bandoh, N., Ogino, T., Katayama, A., et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep 23 (2010), 933–939.
46. Ogino, T., Bandoh, N., Hayashi, T., et al. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 9 (2003), 4043–4051.
47. Ogino, T., Shigyo, H., Ishii, H., et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 66 (2006), 9281–9289.
48. Lopez-Albaitero, A., Nayak, J.V., Ogino, T., et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176 (2006), 3402–3409.
49. Meissner, M., Reichert, T.E., Kunkel, M., et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11 (2005), 2552–2560.
50. Ferris, R.L., Hunt, J.L., Ferrone, S., Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33 (2005), 113–133.
51. Ferris, R.L., Whiteside, T.L., Ferrone, S., Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12 (2006), 3890–3895.
52. Leibowitz, M.S., Srivastava, R.M., Andrade Filho, P.A., et al. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res 19 (2013), 798–808.
53. Pollack, B.P., EGFR inhibitors, MHC expression and immune responses: can EGFR inhibitors be used as immune response modifiers?. Oncoimmunology 1 (2012), 71–74.
54. Marincola, F.M., Jaffee, E.M., Hicklin, D.J., et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74 (2000), 181–273.
55. Leibowitz, M.S., Andrade Filho, P.A., Ferrone, S., et al. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 60 (2011), 525–535.
56. You, M., Zhao, Z., Positive effects of SH2 domain-containing tyrosine phosphatase SHP-1 on epidermal growth factor- and interferon-gamma-stimulated activation of STAT transcription factors in HeLa cells. J Biol Chem 272 (1997), 23376–23381.
57. Grossmann, K.S., Rosario, M., Birchmeier, C., et al. The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res 106 (2010), 53–89.
58. Tao, X.H., Shen, J.G., Pan, W.L., et al. Significance of SHP-1 and SHP-2 expression in human papillomavirus infected Condyloma acuminatum and cervical cancer. Pathol Oncol Res 14 (2008), 365–371.
59. Furcht, C.M., Munoz Rojas, A.R., Nihalani, D., et al. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. Oncogene 32 (2013), 2346–2355.
60. Schrump, D.S., Nguyen, D.M., The epidermal growth factor receptor-STAT pathway in esophageal cancer. Cancer J 7 (2001), 108–111.
61. Kijima, T., Niwa, H., Steinman, R.A., et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 13 (2002), 355–362.
62. Grandis, J.R., Drenning, S.D., Chakraborty, A., et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest 102 (1998), 1385–1392.
63. Buchanan, F.G., Wang, D., Bargiacchi, F., et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278 (2003), 35451–35457.
64. Sriuranpong, V., Park, J.I., Amornphimoltham, P., et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63 (2003), 2948–2956.
65. Colomiere, M., Ward, A.C., Riley, C., et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100 (2009), 134–144.
66. Gao, S.P., Mark, K.G., Leslie, K., et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117 (2007), 3846–3856.
67. Duffy, S.A., Taylor, J.M., Terrell, J.E., et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113 (2008), 750–757.
68. Leeman, R.J., Lui, V.W., Grandis, J.R., STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6 (2006), 231–241.
69. Regis, G., Pensa, S., Boselli, D., et al. Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 19 (2008), 351–359.
70. Fletcher, S., Drewry, J.A., Shahani, V.M., et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 87 (2009), 825–833.
71. Zhang, X., Zhang, J., Wang, L., et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer, 7, 2007, 149.
72. Wang, T., Niu, G., Kortylewski, M., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10 (2004), 48–54.
73. Kortylewski, M., Kujawski, M., Wang, T., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11 (2005), 1314–1321.
74. Smith, B.D., Smith, G.L., Carter, D., et al. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18 (2000), 2046–2052.
75. Riedel, F., Gotte, K., Schwalb, J., et al. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257 (2000), 332–336.
76. Argiris, A., Kotsakis, A.P., Hoang, T., et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 24 (2013), 220–225.
77. Gabrilovich, D.I., Chen, H.L., Girgis, K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996), 1096–1103.
78. Yang, A.S., Lattime, E.C., Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63 (2003), 2150–2157.
79. Yue, F.Y., Dummer, R., Geertsen, R., et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 71 (1997), 630–637.
80. Salazar-Onfray, F., Charo, J., Petersson, M., et al. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 159 (1997), 3195–3202.
81. Shiboski, C.H., Schmidt, B.L., Jordan, R.C., Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer 103 (2005), 1843–1849.
82. Conway, D.I., Stockton, D.L., Warnakulasuriya, K.A., et al. Incidence of oral and oropharyngeal cancer in United Kingdom (1990–1999)—recent trends and regional variation. Oral Oncol 42 (2006), 586–592.
83. Hammarstedt, L., Dahlstrand, H., Lindquist, D., et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol 127 (2007), 988–992.
84. Ramqvist, T., Dalianis, T., An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 31 (2011), 1515–1519.
85. Marur, S., D'Souza, G., Westra, W.H., et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11 (2010), 781–789.
86. Wilczynski, S.P., Lin, B.T., Xie, Y., et al. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 152 (1998), 145–156.
87. Furniss, C.S., McClean, M.D., Smith, J.F., et al. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 120 (2007), 2386–2392.
88. Fakhry, C., Gillison, M.L., Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24 (2006), 2606–2611.
89. Hoffmann, T.K., Schirlau, K., Sonkoly, E., et al. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 124 (2009), 2589–2596.
90. Lee, S.C., Srivastava, R.M., Lopez-Albaitero, A., et al. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 50 (2011), 248–254.
91. Rudensky, A.Y., Regulatory T cells and Foxp3. Immunol Rev 241 (2011), 260–268.
92. Sakaguchi, S., Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 (2000), 455–458.
93. Sakaguchi, S., Yamaguchi, T., Nomura, T., et al. Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
94. Strauss, L., Bergmann, C., Szczepanski, M., et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13 (2007), 4345–4354.
95. Mooradian, D.L., Purchio, A.F., Furcht, L.T., Differential effects of transforming growth factor beta 1 on the growth of poorly and highly metastatic murine melanoma cells. Cancer Res 50 (1990), 273–277.
96. Nishikawa, H., Kato, T., Tawara, I., et al. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 175 (2005), 4433–4440.
97. Larmonier, N., Marron, M., Zeng, Y., et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 56 (2007), 48–59.
98. Zorn, E., Nelson, E.A., Mohseni, M., et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108 (2006), 1571–1579.
99. Mantovani, A., Sica, A., Sozzani, S., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25 (2004), 677–686.
100. Duluc, D., Delneste, Y., Tan, F., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110 (2007), 4319–4330.
101. Munn, D.H., Mellor, A.L., Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117 (2007), 1147–1154.
102. Machiels, J.P., Subramanian, S., Ruzsa, A., et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12 (2011), 333–343.
103. Ramakrishnan, M.S., Eswaraiah, A., Crombet, T., et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 1 (2009), 41–48.
104. Allan, D.G., Nimotuzumab: evidence of clinical benefit without rash. Oncologist 10 (2005), 760–761.